Monitor progress in Phase 3 trials and upcoming topline data in wet AMD (mid-2026) and DME (2H 2027) as key catalysts. Any safety issues or delays could negatively impact valuation, while positive data may drive upside.
Price Chart
Executive Summary
EyePoint, Inc. announced the first patient dosed in both Phase 3 COMO and CAPRI trials for DURAVYU (vorolanib intravitreal insert) in diabetic macular edema (DME), marking a key milestone in its clinical development. Topline data from these trials are expected in the second half of 2027, with DURAVYU positioned as a potential first-in-class TKI therapy for DME with sustained six-month dosing.
Key Facts
- First patients dosed in Phase 3 COMO and CAPRI trials for DURAVYU in DME, a significant clinical milestone.
- DURAVYU is an investigational sustained-delivery TKI therapy targeting VEGF, PDGF, and IL-6 pathways in DME.
- Phase 3 trials are global, randomized, double-masked, and non-inferiority vs. aflibercept, enrolling ~240 patients each.
- Primary endpoint is non-inferiority in BCVA change at weeks 52 and 56; topline data expected in 2H 2027.
- DURAVYU is also in Phase 3 for wet AMD, with data expected beginning mid-2026.
- No safety signals observed in over 190 patients across four completed trials.
Financial Impact
No immediate financial impact; potential long-term commercial upside in multi-billion-dollar DME and wet AMD markets if approved.
Risk Factors
- Clinical trial results may not replicate Phase 2 success; interim data subject to change.
- Regulatory delays or failure to obtain FDA/EMA approval.
- Competition from existing and emerging anti-VEGF and sustained-release therapies.
- Cash runway uncertainty and potential need for future financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247217 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 19, 2026 7d ago | 8-K | $0.4400 $0.3707 | ▲ +15.75% | ▲ +15.61% | $0.3700 (+15.91%) |
Oct 19, 2026 7d ago | Press Release | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 7, 2026 19d ago | SC 13G/A | $3.32 $3.01 | ▼ −9.34% | ▼ −8.36% | $0.3700 (−88.86%) |
Sep 10, 2026 6w ago | 8-K | $4.25 $3.99 | ▼ −6.12% | ▼ −5.62% | $0.3700 (−91.29%) |
Aug 18, 2026 9w ago | Insider Buy | $6.30 $4.99 | ▼ −20.79% | ▼ −20.41% | $0.3700 (−94.13%) |
Aug 17, 2026 10w ago | 8-K | $4.87 $4.87 | · 0.00% | ▲ +1.19% | $0.3700 (−92.40%) |
Aug 5, 2026 11w ago | 8-K | $12.25 $13.53 | ▲ +10.45% | ▲ +10.10% | $0.3700 (−96.98%) |
Jul 30, 2026 12w ago | 8-K | $12.86 $12.83 | ▼ −0.23% | ▼ −3.86% | $0.3700 (−97.12%) |
Jun 22, 2026 18w ago | 8-K | $13.73 $14.11 | ▲ +2.77% | ▲ +3.22% | $0.3700 (−97.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers